L-BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancer

Bibliography

• JEMAL A, SIEGEL R, MURRAY T, XU J, THUN MJ: Cancer statistics, 2007. CA Cancer J. Clin. (2007) 57(1):43-66.
   PubMed Web of Science ®Google Scholar
• KRAMER BS, BROWN ML, PROROK PC, POTOSKY AL, GOHAGAN JK: Prostate cancer screening: what we know and what we need to know. Ann. Intern. Med. (1993) 119(9):914-923.
   PubMed Web of Science ®Google Scholar
• POUND CR, PARTIN AW, EISENBERGER MA et al.: Natural history of progression after PSA elevation following radical prostatectomy. JAMA (1999) 281(17):1642-1645.
   PubMed Web of Science ®Google Scholar
• FREEDLAND SJ, HUMPHREYS EB, MANGOLD LA et al.: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA (2005) 294(4):433-439.
   PubMed Web of Science ®Google Scholar
• HO SB, NIEHANS GA, LYFTOGT C et al.: Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res. (1993) 53(3):641-651.
   PubMed Web of Science ®Google Scholar
• ZOTTER S, HAGEMAN PC, LOSSNITZER A, MOOI WJ, HILGERS J: Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev. (1988) 11-12:55-101.
   Web of Science ®Google Scholar
• KIRSCHENBAUM A, ITZKOWITZ SH, WANG JP et al.: MUC1 expression in prostate carcinoma: correlation with grade and stage. Mol. Urol. (1999) 3(3):163-168.
   PubMedGoogle Scholar
• PARRY G, BECK JC, MOSS L, BARTLEY J, OJAKIAN G: Determination of apical membraned polarity of mammary epithelial cell cultures: the role of cell–cell, cell–substratum, and membrane–cytoskeleton interactions. Exp. Cell. Res. (1990) 188:302-311.
   PubMed Web of Science ®Google Scholar
• WONG RCK, REMOLD-O'DONNELL E, VERCELLI D et al.: Signal transduction via leukocyte antigen CD43 (sialophorin). Feedback regulation by protein kinase C. J. Immunol. (1990) 144(4):1455-1460.
   PubMed Web of Science ®Google Scholar
• DEVINE PL, MCKENZIE IFC: Mucins: structure, function, and associations with malignancy. Bioessays (1992) 14:619-625.
   PubMed Web of Science ®Google Scholar
• KARSTEN U, VON MENSDORFF-POUILLY S, GOLETZ S: What makes MUC1 a tumor antigen. Tumor Biol. (2005) 26:217-220.
   PubMed Web of Science ®Google Scholar
• LI Y, REN J, YU W et al.: The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and β-catenin. J. Biol. Chem. (2001) 276(38):35239-35242.
   PubMed Web of Science ®Google Scholar
• SANGHA R, BUTTS C: L-BLP25: a peptide vaccine strategy in non-small cell lung cancer. Clin. Cancer Res. (2007) 13(15 Suppl.):S4652-S4654.
   PubMed Web of Science ®Google Scholar
• HUANG L, CHEN D, LIU D et al.: MUC1 oncoprotein blocks glycogen synthase kinase 3β-mediated phosphorylation and degradation of β-catenin. Cancer Res. (2005) 65:10413-10422.
   PubMed Web of Science ®Google Scholar
• RAHN JJ, CHOW JW, HORNE GJ et al.: MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1. Clin. Exp. Metast. (2005) 22:475-483.
   PubMed Web of Science ®Google Scholar
• YIN L, LI Y, REN J, KUWAHARA H, KUFE D: Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J. Biol. Chem. (2003) 278:35458-35464.
   PubMed Web of Science ®Google Scholar
• YIN L, HUANG L, KUFE D: MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress. J. Biol. Chem. (2004) 279:45721-45727.
   PubMed Web of Science ®Google Scholar
• WEI X, XU H, KUFE D: Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell (2005) 7:167-178.
   PubMed Web of Science ®Google Scholar
• REN J, AGATA N, CHEN D et al.: Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell (2004) 5:163-175.
   PubMed Web of Science ®Google Scholar
• REDDISH MA, MACLEAN GD, POPPEMA S, BERG A, LONGENECKER BM: Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol. Immunother. (1996) 42:303-309.
   PubMed Web of Science ®Google Scholar
• AGRAWAL B, KRANTZ MJ, REDDISH MA, LONGENECKER BM: Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat. Med. (1998) 4:43-49.
   PubMed Web of Science ®Google Scholar
• HILTBOLD EM, VLAD AM, CIBROWSKI P, WATKINS SC, FINN OJ: The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J. Immunol. (2000) 165:3730-3741.
   PubMed Web of Science ®Google Scholar
• MERRIFIELD RB: Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J. Am. Clin. Soc. (1963) 85:2149-2154.
   Web of Science ®Google Scholar
• ULRICH JT, MYERS KR: Monophosphoryl lipid A as an adjuvant. In: Vaccine Design: The Subunit and Adjuvant Approach. Powell MF et al. (Eds), Plenum Press, New York, USA (1995).
   Google Scholar
• FRIES LF, GORDON DM, RICHARDS RL et al.: Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc. Natl. Acad. Sci. USA (1992) 89(1):358-362.
   PubMed Web of Science ®Google Scholar
• JEROME KR, BARND DL, BENDT KM et al.: Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. (1991) 51(11):2908-2916.
   PubMed Web of Science ®Google Scholar
• BERD D, MAGUIRE HC Jr, MCCUE P, MASTRANGELO M: Treatment of metastatic melanoma with an autologous tumour-cell vaccine: clinical and immunological results in 64 patients. J. Clin. Oncol. (1990) 8(11):1858-1867.
   PubMed Web of Science ®Google Scholar
• IOANNIDES CG, FISK B, JEROME KR, IRIMURA T, WHARTON JT, FINN OJ: Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J. Immunol. (1993) 151(7):3693-3703.
   PubMed Web of Science ®Google Scholar
• JEROME KR, DOMENECH N, FINN OJ: Tumour-specific cytotoxic T-cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B-cells transfected with polymorhphic epithelial mucin complementary DNA. J. Immunol. (1993) 151(3):1654-1662.
   PubMed Web of Science ®Google Scholar
• MASTRANGELO MJ, BERD D, MAGUIRE HC Jr: The immunoaugmenting effects of cancer chemotherapeutic agents. Semin. Oncol. (1986) 13:186.
   PubMed Web of Science ®Google Scholar
• KO HJ, KIM YJ, KIM YS et al.: A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. (2007) 67(15):7477-7486.
   PubMed Web of Science ®Google Scholar
• LUTSIAK MEC, SEMNANI RT, DE PASCALIS R et al.: Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood (2005) 105(7):2862-2868.
   PubMed Web of Science ®Google Scholar
• GHIRINGHELLI F, MENARD C, PUIG PE et al.: Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. (2007) 56(5):641-648.
   PubMed Web of Science ®Google Scholar
• RANGANATHAN A, MURRAY N: Therapeutic cancer vaccines for the management of non-small cell lung cancer. Oncol. Brief. Physician's Educ. Res. (2006) 4(6):1-3.
   Google Scholar
• AGRAWAL B, KRANTZ MJ, REDDISH MA, LONGENECKER BM: Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes. Int. Immunol. (1998) 10:1907-1916.
   PubMed Web of Science ®Google Scholar
• GUAN HH, BUDZYNSKI W, KOGANTY RR et al.: Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses. Bioconjug. Chem. (1998) 9:451-458.
   PubMed Web of Science ®Google Scholar
• PALMER M, PARKER J, MODI S et al.: Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin. Lung Cancer (2001) 3:49-57.
   PubMedGoogle Scholar
• NORTH S, BUTTS C: Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers. Expert Rev. Vaccines (2005) 4:249-257.
   PubMed Web of Science ®Google Scholar
• BUTTS C, MURRAY N, MAKSYMIUK A et al.: Randomized Phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol. (2005) 23:6674-6681.
   PubMed Web of Science ®Google Scholar
• NORTH SA, GRAHAM K, BODNAR D, VENNER P: A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy. J. Urol. (2006) 176:91-95.
   PubMed Web of Science ®Google Scholar
• BUBLEY GJ, CARDUCCI M, DAHUT W et al.: Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer: recommendations from the PSA working group. J. Clin. Oncol. (1999) 17(11):3461-3467.
   PubMed Web of Science ®Google Scholar
• D'AMICO AV, MOUL J, CARROLL PR et al.: Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J. Urol. (2004) 172:S42-46.
   PubMedGoogle Scholar
• AMLING CL, BERGSTRALH EJ, BLUTE ML, SLEZAK JM, ZINCKE H: Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J. Urol. (2001) 165:1146-1151.
   PubMed Web of Science ®Google Scholar
• SQUIBAN P, VELU T, MENNECIER M: MVA-MUC1-IL2 vaccine immunotherapy for advanced non small cell lung cancer (NSCLC): interim Phase II data. 2004 Annual Meeting Proceedings. (Post Meeting Edition). J. Clin. Oncol. (2004) 22(14S):2544.
   Google Scholar
• KONTANI K, TAGUCHI O, OZAKI Y et al.: Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. Int. J. Mol. Med. (2003) 12(4):493-502.
   PubMed Web of Science ®Google Scholar